discussion The therapeutic options for refractory carcinoid syndrome are limited. The
development of new targeted agents for the treatment of neuroendocrine tumors (NET) has …

Opinion statement Carcinoid syndrome (CS) is a complex disorder caused by functional
neuroendocrine tumors (NETs). This debilitating disease is characterized by hyper-secretion …

Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, increases progression-free
survival in patients with advanced neuroendocrine tumours. Patients with neuroendocrine …

Carcinoid syndrome, a paraneoplastic condition linked with the release of multiple humoral
factors, affects around 30-40% of patients with well-differentiated neuroendocrine tumours …

This review reports on the currently available medical treatment options for the control of
symptoms due to carcinoid syndrome in patients with neuroendocrine tumors. The efficacy …

Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in
patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs …

INTRODUCTION—Carcinoid tumors are neuroendocrine tumors (NETs) that originate in the
digestive tract, lungs, or rare primary sites, such as kidneys or ovaries. The term" carcinoid" …

Opinion statement Carcinoids are rare endocrine tumors that can develop in several organs
in the body. Clinically, patients can have a wide spectrum of signs and symptoms that range …

Approximately 30-40% of patients with well-differentiated neuroendocrine tumors present
with carcinoid syndrome, which is a paraneoplastic syndrome associated with the secretion …

“Carcinoids” are mostly slow-growing neuroendocrine neoplasms (NENs) with low
proliferative activity. A wide range of therapeutic options with variable efficacy exist …